Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2934 in systemic light chain amyloidosis (Phase Ib/II)
CTR20254658Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2934 in light-chain amyloidosis, sponsored by Nanjing Shunxin Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
TQB2934
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on CTR20254658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254658.